Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
SynKinase
BMS-5
CHF 0.00
In stock
SYN-1024-M0011 mgCHF 114.00
SYN-1024-M0055 mgCHF 170.00
SYN-1024-M01010 mgCHF 255.00
SYN-1024-M05050 mgCHF 780.00
SYN-1024-M100100 mgINQ
| Product Details | |
|---|---|
| Synonyms | BMS5 |
| Product Type | Chemical |
| Properties | |
| Formula | C17H14Cl2F2N4OS |
| MW | 431.3 |
| CAS | 1338247-35-0 |
| Purity Chemicals | ≥95% |
| Appearance | Solid. |
| Solubility | Soluble in DMSO. |
| Declaration | Manufactured by SynKinase. |
| Other Product Data |
Target: LIMK1 - LIMK2 | Kinase Group: TKL | Substrate: Serine-Threonine Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
| InChi Key | IVUGBSGLHRJSSP-UHFFFAOYSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Kinases, such as LIM kinase 1 (LIMK1) and LIM kinase 2 (LIMK2), have been identified as participating in signal pathways affecting actin dynamics by deactivating cofilin. Over expression of LMK1 has been found in invasive breast and prostate cancer cell lines and suppression of LIMK 2 expression has been found to limit migration of human fibrosarcoma cells. Thus, the inhibition of LIMK1 and/or LIMK2 enzymes have been suggested as targets for treating cancer, including reduction or prevention of metastasis. BMS-5 is a potent inhibitor of the LIM kinase. It has IC(50) values of 7nM and 8nM for LIMK1 and LIMK2 respectively. LIMK1/2 activity was measured via TCA precipitation assay using a biotinylated ADF (actin depolymization factor) as the protein substrate and the kinase domains of LIMK1 and LIMK2 as the enzyme sources in the presence of 1µM ATP.
Product References
- Phenyl-substituted pyrimidine compounds useful as kinase inhibitors: S.T. Wrobelski, et al.; WO2006084017 (2006)
- Computer-Based Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton: E. Mashiach-Farkash, et al.; Oncotarget 3, 629 (2012)
- LIM kinase regulation of cytoskeletal dynamics is required for salivary gland branching morphogenesis: S. Ray, et al.; Mol. Biol. Cell 25, 2393 (2014)